Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
IKT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.12 - $4.20
Previous CloseN/A
Volume38.02K
Average Volume (3M)194.26K
Market Cap
$226.12M
Enterprise Value$8.45M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Mar 27, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.72
Shares Outstanding69,362,440
10 Day Avg. Volume193,392
30 Day Avg. Volume194,264
Standard Deviation0.32
R-Squared0.02
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1055.99
Price to Cash Flow (P/CF)-10.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.63
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$8.00Price Target Upside145.40% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Inhibikase Therapeutics News
PremiumCompany Announcements
Inhibikase Therapeutics Appoints Mark Iwicki as New CEOPremiumCompany Announcements
Inhibikase Adjusts and Terminates Stock Offering Agreement
PremiumCompany Announcements
Inhibikase Therapeutics Reports Q3 2024 Financial Results
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsIkT-001Pro is being developed to address unmet needs in pulmonary arterial hypertension, representing a significant opportunity despite being a rare disease.
Financial PerformanceThe company raised $110M in gross proceeds, which is expected to provide sufficient runway into 2027.
Regulatory PathwayFDA has agreed to an accelerated 505(b)(2) pathway, allowing IKT to leverage imatinib's existing approval for a potentially faster development process.
Bears Say
Clinical Trial ResultsRisvodetinib development paused following results from Phase 2 201 trial, as it did not demonstrate an improvement in the top hierarchical efficacy measure.
Execution RiskThere is still execution and clinical risk over the medium to longer term for PAH treatment.
Stock RatingAnalyst's rating downgraded to Neutral from Buy due to the company’s decision to halt further development of risvodetinib.
---
Ownership Overview
10.53% Insiders
0.13% Mutual Funds
66.08% Other Institutional Investors
19.29% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IKT FAQ
What was Inhibikase Therapeutics’s price range in the past 12 months?
Inhibikase Therapeutics lowest stock price was $1.12 and its highest was $4.20 in the past 12 months.
What is Inhibikase Therapeutics’s market cap?
Inhibikase Therapeutics’s market cap is $226.12M.
When is Inhibikase Therapeutics’s upcoming earnings report date?
Inhibikase Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 33 days.
How were Inhibikase Therapeutics’s earnings last quarter?
Inhibikase Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.48 by -$0.17.
Is Inhibikase Therapeutics overvalued?
According to Wall Street analysts Inhibikase Therapeutics’s price is currently Undervalued.
Does Inhibikase Therapeutics pay dividends?
Inhibikase Therapeutics does not currently pay dividends.
What is Inhibikase Therapeutics’s EPS estimate?
Inhibikase Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Inhibikase Therapeutics have?
Inhibikase Therapeutics has 69,362,440 shares outstanding.
What happened to Inhibikase Therapeutics’s price movement after its last earnings report?
Inhibikase Therapeutics reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.48. Following the earnings report the stock price went down -2.479%.
Which hedge fund is a major shareholder of Inhibikase Therapeutics?
Currently, no hedge funds are holding shares in IKT
---
Inhibikase Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.00 (145.40% Upside)
$8.00 (145.40% Upside)
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 10.2%
Last 30 Days ▼ 10.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.98%
12-Months-Change
Fundamentals
Return on Equity
-270.10%
Trailing 12-Months
Asset Growth
-75.52%
Trailing 12-Months
Company Description
Inhibikase Therapeutics
Inhibikase Therapeutics Inc is a clinical stage pharmaceutical company developing therapeutics for Parkinson's Diseases and related disorders inside and outside the brain. Its pipeline product, IkT-148009, targets underlying disease mechanisms to reverse the course of Parkinson's disease and the GI complications of Parkinson's disease.
---
IKT Stock 12 Month Forecast
Average Price Target
$8.00
▲(145.40% Upside)
Technical Analysis
Best Analysts Covering IKT
1 Year
1 Year Success Rate
6/6 ratings generated profit
1 Year Average Return
+49.08%
reiterated a buy rating 3 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +49.08% per trade.
---